Micromedic Technologies Ltd. (TASE:MCTC) reports 90% sensitivity in a trial for its diagnostic biomarker kit for breast and ovarian cancer. The kit was developed at Hadassah Medical Organization in Jerusalem by a team headed by Dr. Asher Salmon.
Micromedic said that, in view of the results, it would begin a larger trial at several medical centers in Israel and the US.
A similar diagnostic kit on the market costs $3,120, and has annual sales of $300 million.
Micromedic's share fell 3.1% at the opening on the TASE today to NIS 7.50, giving a market cap of NIS 85.9 million.
Published by Globes [online], Israel business news - www.globes-online.com - on November 1, 2009
© Copyright of Globes Publisher Itonut (1983) Ltd. 2009